Yusheng Han

CEO&Founder

Founder of Burning Rock, established Burning Rock in 2014, engaged in investment of medical fields; with successful experience in establishing and operating a start-up team; with sixteen years of working experience in the field of life science.


Established Burning Rock


Investment manager of top-rank VC Northern Light Venture Capital


MBA from Columbia University


General manager of BioTek Instrument China Region


Cell biology master of Peking Union Medical College

Shannon Chuai

COO

Co-founder of Burning Rock. With 13 years of experience in the field of bioinformatics and translational medicine, mastered internationally leading technologies, accumulated R& D experience in tumor individualistic diagnosis and treatment related areas such as NGS data analysis, molecular diagnosis,etc. 


Novartis (China) R& D Center: Supervisor of the bioinformatics platform


Chief Statistical Analyst of Novartis (America), University of Pennsylvania


Experiment designer and data analyst of Sloan-Katherine Cancer Center of New York


University of Pennsylvania: Biostatistics Ph.D.


University of Texas: Statistics and Applied Mathematics Master

Hao Liu

CMO

With 14 years of clinical R&D experience with a foreign-owned pharmaceutical company. Ever took charge of clinical development of several important declining drugs in China, such as Crizotinib, ceritinib, axitinib, velcade, etc.


Novartis: Took charge of all research strategies and projects of solid tumors in China. A senior person with richest development experience of ALK TKI in China (no one else has the all-course experience in the development of ALK TKI of the first and second generation)


Pfizer: Took charge of all clinical researches of star drug Crizotinib. A soul-level tutor and person in charge of development of Crizotinib in China.


Worked in a tumor hospital of Chinese Academy of Medical Sciences for five years

Joe Zhang

CTO

With working experience in the field of NGS for over 10 years. Ever participated in research and development of several products, successfully released kits such as Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA as a leader of the core team, and made outstanding contribution to the fast development of NGS


A senior scientist of Illumina. A senior researcher of genome science department of Howard Hughes Institute of Medicine of University of Washington


Duke University: Ph.D. of molecular genetics and microbiology

Simon Wu

Vice President for Business Development

With above ten years of experience in life science and medicine and with rich experience in marketing and project management


Co-founder of Burning Rock


Gene Co., Ltd. General manager for China Region with the department of large applied instrument


Gene Co., Ltd. Project manager for China Region (applied industry)


Nanjing Normal University Biotech

Dan Zhou

Sales Vice President for Tumor Early Detection

Focused on sales of in vitro diagnostic agent for above 16 years, with rich marketing management and business expansion capabilities.


Worked as a sales supervisor for South China region in QIAGEN Business Management (Shanghai) Co., Ltd.


Worked as a market explorer in South China regionBeijing Jinpujia Medical Technology Co., Ltd.


Gene (Hong Kong) Co., Ltd.: Sales of Denmark DAKO, America BD, Abbott VYSIS diagnosis reagent, pathology, streaming and blood departments of Guangdong and Fujian


Shandong Liming Polytechnic Vocational College